Cancer‐related mortality at maximal · people with unprovoked VTE
Standard testing plus PET/CT scanning showed no clear difference in cancer‐related mortality3 compared with standard testing alone (moderate certainty).
1 finding from 1 review
VTE‐related mortality4 · people with unprovoked VTE
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
VTE‐related morbidity5 · people with unprovoked VTE
Standard testing plus PET/CT scanning showed no clear difference in VTE‐related morbidity5 compared with standard testing alone (moderate certainty).
1 finding from 1 review
Stage at diagnosis (early-stage detection) · people with unprovoked VTE
Standard testing plus PET/CT scanning showed no clear difference in stage of cancer ‐ early compared with standard testing alone (low certainty).
1 finding from 1 review
Stage of cancer ‐ advanced · people with unprovoked VTE
Standard testing plus PET/CT scanning showed no clear difference in stage of cancer ‐ advanced compared with standard testing alone (low certainty).
1 finding from 1 review
Time to cancer diagnosis7 · people with unprovoked VTE
1 finding from 1 review
Frequency of an underlying cancer diagnosis8 · people with unprovoked VTE
Standard testing plus PET/CT scanning showed no clear difference in frequency of an underlying cancer diagnosis8 compared with standard testing alone (moderate certainty).
1 finding from 1 review
All‐cause mortality1 · people with unprovoked VTE
Standard testing plus PET/CT scanning showed no clear difference in all‐cause mortality1 compared with standard testing alone (moderate certainty).
1 finding from 1 review
Sensitivity · Oral cavity cancer or potentially malignant disorder symptom-free individuals with tobacco habits
1 finding from 1 review
Whitening (bleaching) efficacy · Demineralised / white-spot-lesion enamel (in vitro specimens)
Low-quality in vitro evidence indicates that adding fluoride or other remineralising agents does not impair the whitening/bleaching effect (ungraded).
1 finding from 1 review
Endometrial Polyps · endometrial protection in women with breast cancer on adjuvant tamoxifen
The LNG‐IUS with endometrial surveillance probably leads to lower endometrial polyps compared with endometrial surveillance alone (moderate certainty).
1 finding from 1 review
Endometrial Hyperplasia · endometrial protection in women with breast cancer on adjuvant tamoxifen
The LNG‐IUS with endometrial surveillance probably leads to lower endometrial hyperplasia compared with endometrial surveillance alone (moderate certainty).
1 finding from 1 review
Endometrial cancer · endometrial protection in women with breast cancer on adjuvant tamoxifen
1 finding from 1 review
Fibroids · endometrial protection in women with breast cancer on adjuvant tamoxifen
The LNG‐IUS with endometrial surveillance showed no clear difference in fibroids compared with endometrial surveillance alone (moderate certainty).
1 finding from 1 review
Abnormal Vaginal Bleeding or Spotting · endometrial protection in women with breast cancer on adjuvant tamoxifen
The LNG‐IUS with endometrial surveillance probably leads to higher abnormal vaginal bleeding or spotting compared with endometrial surveillance alone (moderate certainty).
1 finding from 1 review
Breast cancer recurrence · endometrial protection in women with breast cancer on adjuvant tamoxifen
The LNG‐IUS with endometrial surveillance showed no clear difference in breast cancer recurrence compared with endometrial surveillance alone (moderate certainty).
1 finding from 1 review
Breast Cancer‐related Death · endometrial protection in women with breast cancer on adjuvant tamoxifen
The LNG‐IUS with endometrial surveillance showed no clear difference in breast cancer‐related death compared with endometrial surveillance alone (moderate certainty).
1 finding from 1 review
Proportion of participants with re‐epithelialization and complete healing with or without scar formation at 4 to 8 weeks Assessed by slit‐lamp biomicroscopy · participants of any age with confirmed cases of bacterial keratitis
1 finding from 1 review
no estimate extracted
15 participants
Very low
Proportion of participants with BCVA of 20/100 or better at 4 to 8 weeks Assessed using a logMAR chart · participants of any age with confirmed cases of bacterial keratitis
1 finding from 1 review
no estimate extracted
12 participants
Very low
Mean change from baseline in BCVA at 4 to 8 weeks Assessed using a logMAR chart · participants of any age with confirmed cases of bacterial keratitis
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported